LeMaitre Vascular, Inc. (NASDAQ:LMAT), might not be a large cap stock, but it saw a decent share price growth of 10% on the NASDAQGM over the last few months. While good news for shareholders, the company has traded much higher in the past year. As a mid-cap stock with high coverage by analysts, you could assume any recent changes in the company’s outlook is already priced into the stock. But what if there is still an opportunity to buy? Today we will analyse the most recent data on LeMaitre Vascular’s outlook and valuation to see if the opportunity still exists.

See our latest analysis for LeMaitre Vascular

Is LeMaitre Vascular Still Cheap?

According to our valuation model, LeMaitre Vascular seems to be fairly priced at around 10.58% above our intrinsic value, which means if you buy LeMaitre Vascular today, you’d be paying a relatively reasonable price for it. And if you believe that the stock is really worth $90.02, there’s only an insignificant downside when the price falls to its real value. Furthermore, LeMaitre Vascular’s low beta implies that the stock is less volatile than the wider market.

Can we expect growth from LeMaitre Vascular?

Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company's future expectations. LeMaitre Vascular's earnings over the next few years are expected to increase by 43%, indicating a highly optimistic future ahead. This should lead to more robust cash flows, feeding into a higher share value.

What This Means For You

Are you a shareholder? It seems like the market has already priced in LMAT’s positive outlook, with shares trading around its fair value. However, there are also other important factors which we haven’t considered today, such as the financial strength of the company. Have these factors changed since the last time you looked at the stock? Will you have enough confidence to invest in the company should the price drop below its fair value?

Are you a potential investor? If you’ve been keeping tabs on LMAT, now may not be the most advantageous time to buy, given it is trading around its fair value. However, the positive outlook is encouraging for the company, which means it’s worth further examining other factors such as the strength of its balance sheet, in order to take advantage of the next price drop.

It can be quite valuable to consider what analysts expect for LeMaitre Vascular from their most recent forecasts. Luckily, you can check out what analysts are forecasting by clicking here.

If you are no longer interested in LeMaitre Vascular, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.